Title:
RECOMBINANT FUSION PROTEINS AND THE TRIMERS THEREOF
Document Type and Number:
WIPO Patent Application WO2002090553
Kind Code:
A3
Abstract:
Die vorliegende Anmeldung betrifft rekombinante Fusionsproteine, mit der Eigenschaft, Trimere bilden zu können, wobei die rekombinanten Fusionproteine mindestens eine Komponente A und mindestens eine Komponente B aufweisen, wobei die Komponente B trimerisierende Eigenschaften und die Komponente A biologische Eigenschaften aufweist, sowie Trimere dieser rekombinanten Fusionsproteine. Weiterhin betrifft die vorliegende Erfindung die Verwendung von derartigen Trimeren zur Herstellung eines Arzneimittels bzw. deren Verwendung zur In-vitro-Diagnose bzw. zur Herstellung eines In-vitro-Diagnosenmittels. Auch DNA-Sequenzen, die für ein derartiges Fusionsprotein kodieren, sowie Expressionsvektoren und Wirtszellen, die die DNA-Sequenz bzw. den Expressionsvektor enthalten, sind Gegenstand der vorliegenden Erfindung.
Inventors:
TSCHOPP JUERG (CH)
SCHNEIDER PASCAL (CH)
SCHNEIDER PASCAL (CH)
Application Number:
PCT/EP2002/005103
Publication Date:
May 01, 2003
Filing Date:
May 08, 2002
Export Citation:
Assignee:
APOXIS SA (CH)
TSCHOPP JUERG (CH)
SCHNEIDER PASCAL (CH)
TSCHOPP JUERG (CH)
SCHNEIDER PASCAL (CH)
International Classes:
A61K38/00; A61P1/16; A61P17/00; A61P25/00; A61P29/00; A61P31/14; A61P31/20; C12N15/09; A61P37/02; A61P37/06; A61P43/00; C07K14/47; C07K14/475; C07K14/52; C07K14/525; C07K14/575; C07K14/705; C07K14/715; C07K19/00; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/12; (IPC1-7): C12N15/62; C07K14/47; C07K14/525; C07K19/00; C12N1/21; C12N5/10; A61K38/17
Domestic Patent References:
| WO2001049866A1 | 2001-07-12 |
Foreign References:
| EP0985732A2 | 2000-03-15 |
Other References:
KISHORE U ET AL: "A recombinant homotrimer, composed of the alpha helical neck region of human surfactant protein D and C1q B chain globular domain, is an inhibitor of the classical complement pathway.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 1 JAN 2001, vol. 166, no. 1, 1 January 2001 (2001-01-01), pages 559 - 565, XP002228057, ISSN: 0022-1767
SCHNEIDER P ET AL: "Conversion of membrane-bound FasCD95 ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 187, no. 8, 20 April 1998 (1998-04-20), pages 1205 - 1213, XP002167589, ISSN: 0022-1007
SUDA TAKASHI ET AL: "Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing.", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 186, no. 12, 15 December 1997 (1997-12-15), pages 2045 - 2050, XP002228058, ISSN: 0022-1007
SCHNEIDER P ET AL: "Conversion of membrane-bound FasCD95 ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 187, no. 8, 20 April 1998 (1998-04-20), pages 1205 - 1213, XP002167589, ISSN: 0022-1007
SUDA TAKASHI ET AL: "Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing.", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 186, no. 12, 15 December 1997 (1997-12-15), pages 2045 - 2050, XP002228058, ISSN: 0022-1007
Download PDF:
Previous Patent: USE OF 2'-5'-OLIGOADENYLATE SYNTHETASE AND/OR RNASEL OR NUCLEIC ACIDS ENCODING THEM FOR DIAGNOSIS, P...
Next Patent: CLONING VECTOR
Next Patent: CLONING VECTOR